Mark A. Velleca, President and CEO at G1 Therapeutics, Inc. (GTHX), sold 6,000 shares at $41.86 ($210K) on 2018-07-16, disclosed to the SEC on 2018-07-17.
Open-market sale of $210k GTHX by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 1,000 | $0 | 0.0% |
| 2 | $41.86 | 3,800 | $159K | 75.6% |
| 3 | $42.71 | 1,200 | $51K | 24.4% |
| Total | $35.05 avg | 6,000 | $210K | 100% |
| Filing → |
| GTHX | SELL | 2022-09-22 | $270K | — | Filing → |
| GTHX | SELL | 2022-08-18 | $1.0M | — | Filing → |
| GTHX | SELL | 2021-07-15 | $946K | — | Filing → |